193 related articles for article (PubMed ID: 24270404)
1. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
Merli M; Visco C; Spina M; Luminari S; Ferretti VV; Gotti M; Rattotti S; Fiaccadori V; Rusconi C; Targhetta C; Stelitano C; Levis A; Ambrosetti A; Rossi D; Rigacci L; D'Arco AM; Musto P; Chiappella A; Baldini L; Bonfichi M; Arcaini L
Haematologica; 2014 Mar; 99(3):489-96. PubMed ID: 24270404
[TBL] [Abstract][Full Text] [Related]
2. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
[TBL] [Abstract][Full Text] [Related]
3. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
Carella AM; de Souza CA; Luminari S; Marcheselli L; Chiappella A; di Rocco A; Cesaretti M; Rossi A; Rigacci L; Gaidano G; Merli F; Spina M; Stelitano C; Hohaus S; Barbui A; Puccini B; Miranda EC; Guida A; Federico M
Leuk Lymphoma; 2013 Jan; 54(1):53-7. PubMed ID: 22712840
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
[TBL] [Abstract][Full Text] [Related]
6. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
[TBL] [Abstract][Full Text] [Related]
10. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
13. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Ferrari A; Spina M; Tucci A; Stelitano C; Capodanno I; Fragasso A; Baldini L; Bottelli C; Montechiarello E; Fogazzi S; Lamorgese C; Cavalli L; Federico M;
Leuk Lymphoma; 2014 Jan; 55(1):38-43. PubMed ID: 23517562
[TBL] [Abstract][Full Text] [Related]
14. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
15. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.
Cardesa-Salzmann TM; Colomo L; Gutierrez G; Chan WC; Weisenburger D; Climent F; González-Barca E; Mercadal S; Arenillas L; Serrano S; Tubbs R; Delabie J; Gascoyne RD; Connors JM; Mate JL; Rimsza L; Braziel R; Rosenwald A; Lenz G; Wright G; Jaffe ES; Staudt L; Jares P; López-Guillermo A; Campo E
Haematologica; 2011 Jul; 96(7):996-1001. PubMed ID: 21546504
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
19. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).
Tucci A; Merli F; Fabbri A; Marcheselli L; Pagani C; Puccini B; Marino D; Zanni M; Pennese E; Flenghi L; Arcari A; Botto B; Celli M; Mammi C; Re A; Campostrini G; Tafuri A; Zilioli VR; Cencini E; Sartori R; Bottelli C; Merli M; Petrucci L; Gini G; Balzarotti M; Cavallo F; Musuraca G; Luminari S; Rossi G; Spina M
Haematologica; 2023 Apr; 108(4):1083-1091. PubMed ID: 36384247
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
Visco C; Finotto S
World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
